Why Innovator Companies Need To Take Control Of Their Supply Chains

As drug candidates advance toward approval, supply chain decisions quickly shift from operational details to strategic risk management. This perspective emphasizes why innovator companies must maintain direct control over critical raw materials and supplier relationships rather than delegating them entirely to CDMOs. Early assumptions about volume, cost, and timelines are rarely stable, making transparency and foresight essential. A clear understanding of RSM sourcing enables more accurate cost comparisons, stronger negotiating leverage, and smoother onboarding of secondary suppliers as programs scale. The discussion also highlights how geopolitical pressures, capacity constraints, and pricing volatility can undermine single-source strategies, particularly when critical materials require long lead times and specialized capabilities. Building trusted partnerships, insisting on pricing clarity, and planning for dual sourcing where it matters most helps protect both timelines and budgets. A forward-looking, “boring” supply chain—predictable, resilient, and well-governed—reduces stress, supports commercialization readiness, and creates a repeatable playbook for future programs. Explore the full piece to uncover practical guidance for building that resilience early.